Drip More LLC

CLOSEOUT LETTER Drip More LLC MARCS-CMS 548401 — July 31, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Recipient: Drip More LLC United States Issuing Office: United States Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring, MD 20993 July 31, 2018 VIA UPS and Electronic Mail Brian Bereber Drip More LLC 1110 Palmyrita Ave Ste 120 Riverside, CA 92507 dripmore@gmail.com RE: Warning Letter issued to Drip More LLC(RW1800843) Dear Brian Bereber: On May 1, 2018, the United States Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Candy King Batch and Candy King Sour Worms e-liquid products are misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading . Specifically, FDA determined that the labeling and/or advertising of your Candy King Batch and Candy King Sour Worms e-liquids are misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the products to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. On May 11, 2018, June 7, 2018, June 8, 2018, June 21, 2018, and July 17, 2018, you sent FDA a response to the Warning Letter, and we held teleconferences on June 7, 2018 and July 17, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter. We note that you may have other tobacco products with labeling and/or advertising that causes the product to be misbranded for similar reasons to those discussed above. You are responsible for taking any necessary actions to bring your tobacco products into compliance with the requirements of the law. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov . Sincerely, /S/ Ele Ibarra-Pratt Division Director Office of Compliance and Enforcement Center for Tobacco Products VIA UPS and Electronic Mail cc: Azim Chowdhury Keller and Heckman LLP 1001 G Street NW Washington, DC 20001 chowdhury@khlaw.com Brian Bereber Brian.allstarglass@gmail.com Drip More LLC irene@dripmore.com Godaddy.com LLC abuse@godaddy.com Shopify, Inc. abuse@shopify.com Content current as of: 08/23/2018